{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:07:17Z","timestamp":1791292037322,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014882","name":"Hebei Provincial Department of Finance","doi-asserted-by":"crossref","award":["ZF2025070"],"award-info":[{"award-number":["ZF2025070"]}],"id":[{"id":"10.13039\/501100014882","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Aims<\/jats:title>\n<jats:p>This study aimed to investigate the efficacy and safety of finerenone in the treatment of diabetic kidney disease (DKD) in the real-world medical setting and explore the underlying mechanism of its kidney-protecting effects from the perspective of the inflammatory response.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and Methods<\/jats:title>\n<jats:p>Forty-eight DKD patients were selected and completed a 6-month finerenone treatment. Renal parameters, inflammatory cytokines, other related indicators and adverse effects were collected at every visit. Additionally, subgroup analysis was conducted on the microalbuminuria group (baseline urinary albumin\/creatinine ratio (UACR) 30 \u2013\u2009&lt;\u2009300 mg\/g) and the macroalbuminuria group (baseline UACR\u2009\u2265\u2009300 mg\/g).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>After finerenone treatment, the levels of UACR, urinary \u03b22-microglobulin (\u03b22-MG) and proinflammatory cytokines in patients decreased compared with the pretreatment levels. Moreover, the rates of decrease in the UACR levels in the macroalbuminuria group were significantly greater than those in the microalbuminuria group. In the initial stage of treatment, the patient\u2019s estimated glomerular filtration rate (eGFR) level decreased and serum potassium level increased compared to before, but with prolongation of the treatment time, both eGFR and serum potassium levels remained stable.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>With the assistance of RAS inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, finerenone effectively reduces urinary protein and improves the inflammatory response, demonstrating relatively manageable safety in real-world DKD treatment. The patients with macroalbuminuria may experience greater benefits.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0329965","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T17:24:35Z","timestamp":1755537875000},"page":"e0329965","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of finerenone on urinary protein and inflammatory factor levels in type 2 diabetes mellitus patients with diabetic kidney disease"],"prefix":"10.1371","volume":"20","author":[{"given":"Jia","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiNa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuQing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinJu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShanShan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiMeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingMin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6542-2159","authenticated-orcid":true,"given":"AiGe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"pone.0329965.ref001","doi-asserted-by":"crossref","first-page":"892860","DOI":"10.3389\/fendo.2022.892860","article-title":"The burden of diabetes-related chronic kidney disease in China from 1990 to 2019","volume":"13","author":"X Pan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"pone.0329965.ref002","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"RZ Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0329965.ref003","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"S Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"key":"pone.0329965.ref004","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejphar.2008.06.019","article-title":"Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats","volume":"589","author":"M Taira","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"pone.0329965.ref005","article-title":"The mineralocorticoid receptor in diabetic kidney disease","volume":"327","author":"G Jia","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"pone.0329965.ref006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"R Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0329965.ref007","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12882-020-01960-0","article-title":"Renal expression of cytokines and chemokines in diabetic nephropathy","volume":"21","author":"LS Ara\u00fajo","year":"2020","journal-title":"BMC Nephrol"},{"key":"pone.0329965.ref008","doi-asserted-by":"crossref","first-page":"609223","DOI":"10.3389\/fphys.2020.609223","article-title":"Patterns of toll-like receptor expressions and inflammatory cytokine levels and their implications in the progress of insulin resistance and diabetic nephropathy in type 2 diabetic patients","volume":"11","author":"RH Aly","year":"2020","journal-title":"Front Physiol"},{"key":"pone.0329965.ref009","doi-asserted-by":"crossref","first-page":"108917","DOI":"10.1016\/j.intimp.2022.108917","article-title":"The role of IL-10 in kidney disease","volume":"108","author":"W Wei","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"pone.0329965.ref010","first-page":"29","article-title":"Systems biology and novel biomarkers for the early detection of diabetic kidney disease","volume":"149","author":"P Villalvazo","year":"2025","journal-title":"Nephron"},{"key":"pone.0329965.ref011","article-title":"Estimated proximal tubule fluid phosphate concentration and renal tubular damage biomarkers in early stages of chronic kidney disease","author":"S Mori","year":"2024","journal-title":"J Ren Nutr"},{"issue":"9","key":"pone.0329965.ref012","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study","volume":"22","author":"KI Birkeland","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"pone.0329965.ref013","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"A Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0329965.ref014","doi-asserted-by":"crossref","first-page":"1125693","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"R Lv","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"pone.0329965.ref015","article-title":"Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"324","author":"L Yao","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"pone.0329965.ref016","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"R Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"23","key":"pone.0329965.ref017","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"GL Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0329965.ref018","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"B Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0329965.ref019","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.ki.5000377","article-title":"Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective","volume":"69","author":"H-H Parving","year":"2006","journal-title":"Kidney Int"},{"issue":"4","key":"pone.0329965.ref020","doi-asserted-by":"crossref","first-page":"108411","DOI":"10.1016\/j.jdiacomp.2023.108411","article-title":"Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice","volume":"37","author":"NR Desai","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"2","key":"pone.0329965.ref021","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ndt\/gfac157","article-title":"Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study","volume":"38","author":"LM Ruilope","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"pone.0329965.ref022","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes\u00a0: a mediation analysis","volume":"176","author":"R Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"pone.0329965.ref023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"HJL Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"pone.0329965.ref024","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2023","volume":"46","author":"NA ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"12","key":"pone.0329965.ref025","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis","volume":"45","author":"P Rossing","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"pone.0329965.ref026","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"AM Shaman","year":"2022","journal-title":"Circulation"},{"key":"pone.0329965.ref027","doi-asserted-by":"crossref","first-page":"4647685","DOI":"10.1155\/2016\/4647685","article-title":"Urinary markers of tubular injury in early diabetic nephropathy","volume":"2016","author":"T Fiseha","year":"2016","journal-title":"Int J Nephrol"},{"issue":"9","key":"pone.0329965.ref028","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jdiacomp.2019.05.013","article-title":"Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: a prospective cohort study","volume":"33","author":"B Satirapoj","year":"2019","journal-title":"J Diabetes Complications"},{"issue":"16","key":"pone.0329965.ref029","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by finerenone-translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"P Kolkhof","year":"2022","journal-title":"Int J Mol Sci"},{"key":"pone.0329965.ref030","doi-asserted-by":"crossref","first-page":"102946","DOI":"10.1016\/j.redox.2023.102946","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy","volume":"68","author":"L Yao","year":"2023","journal-title":"Redox Biol"},{"issue":"2","key":"pone.0329965.ref031","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.15","article-title":"Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes","volume":"1","author":"K Nunoi","year":"2018","journal-title":"Endocrinol Diabetes Metab"},{"key":"pone.0329965.ref032","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2147\/DMSO.S353717","article-title":"Glucagon-like peptide 1 receptor agonist improves renal tubular damage in mice with diabetic kidney disease","volume":"15","author":"R Li","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"pone.0329965.ref033","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/ars.2024.0637","article-title":"Angiotensin-converting enzyme-dependent intrarenal angiotensin II contributes to CTP: phosphoethanolamine cytidylyltransferase downregulation, mitochondrial membranous disruption, and reactive oxygen species overgeneration in diabetic tubulopathy","volume":"42","author":"XQ Li","year":"2025","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"pone.0329965.ref034","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1159\/000098004","article-title":"Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration","volume":"26","author":"JF Navarro","year":"2006","journal-title":"Am J Nephrol"},{"key":"pone.0329965.ref035","first-page":"146154","article-title":"Inflammation in diabetic nephropathy","volume":"2012","author":"AKH Lim","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"2","key":"pone.0329965.ref036","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","article-title":"Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease","volume":"25","author":"RZ Alicic","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"pone.0329965.ref037","doi-asserted-by":"crossref","first-page":"115661","DOI":"10.1016\/j.biopha.2023.115661","article-title":"Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors","volume":"168","author":"M Sanz-G\u00f3mez","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"pone.0329965.ref038","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13098-024-01325-9","article-title":"Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus","volume":"16","author":"R Zhang","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"pone.0329965.ref039","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"SH Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"pone.0329965.ref040","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1002\/jcp.27147","article-title":"Effects of inhibitors of the renin-angiotensin system on reducing blood pressure and expression of inflammatory factors in CHD patients: a network meta-analysis","volume":"234","author":"X-F Pang","year":"2019","journal-title":"J Cell Physiol"},{"issue":"7","key":"pone.0329965.ref041","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40262-022-01124-3","article-title":"Dose-exposure-response analysis of the nonsteroidal mineralocorticoid receptor antagonist finerenone on UACR and eGFR: an analysis from FIDELIO-DKD","volume":"61","author":"SC Goulooze","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"pone.0329965.ref042","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"S Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"31","key":"pone.0329965.ref043","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"B Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"12","key":"pone.0329965.ref044","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s40262-023-01312-9","article-title":"The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone","volume":"62","author":"R Heinig","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"pone.0329965.ref045","doi-asserted-by":"crossref","first-page":"2400541","DOI":"10.1080\/0886022X.2024.2400541","article-title":"Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China","volume":"46","author":"J Zhou","year":"2024","journal-title":"Ren Fail"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T17:24:42Z","timestamp":1755537882000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329965"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329965","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}